How insurance decides who gets Wegovy approved in 2026

TLDR. Insurance plans approve Wegovy and Zepbound when three things line up: a qualifying BMI, a documented comorbidity (or a clean 30-plus BMI), and proof you tried lifestyle change for six months. The three biggest PBMs, CVS Caremark, OptumRx and Express Scripts, run materially different checklists on top of those basics. About 30 to 40 percent of initial PAs are denied. Most denials are reversible. The deciding factor is rarely the patient; it is the clinical documentation the prescriber submits. This walks through the actual decision logic, the PBM differences and what successful PA letters include.

The core checklist every commercial plan uses

The 2026 obesity-medication PA criteria, as adopted by the majority of commercial plans, derive from the American Association of Clinical Endocrinology obesity guideline and from the 2023 American Heart Association statement on obesity as a chronic disease. The criteria converge on five points:

• BMI of 30 or greater, OR BMI of 27 to 29.9 with at least one obesity-related comorbidity
• Documented attempt at lifestyle modification (diet, exercise, behavioral therapy) over a 6-month window
• No contraindication: personal or family history of medullary thyroid carcinoma, MEN2 syndrome, active pancreatitis, severe gastroparesis, pregnancy
• Prescriber attestation that the patient is appropriate for chronic anti-obesity pharmacotherapy
• For Zepbound specifically, some plans require failed semaglutide trial first (step therapy, see below)

Qualifying comorbidities at the BMI 27-29.9 threshold are narrow. The accepted list, drawn from the Wegovy and Zepbound labels, is hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea and atherosclerotic cardiovascular disease. Some plans now accept polycystic ovary syndrome and non-alcoholic fatty liver disease. Most do not yet accept osteoarthritis, gastroesophageal reflux disease or depression as standalone qualifying comorbidities.

The comorbidity codes that matter

ICD-10 codes are how comorbidities reach the PA reviewer. The seven that move the needle for GLP-1 weight-loss PAs:

• E66.01: morbid (severe) obesity due to excess calories (BMI 35-plus)
• E66.811: obesity, class 1 (BMI 30-34.9)
• E66.812: obesity, class 2 (BMI 35-39.9)
• E66.813: obesity, class 3 (BMI 40-plus)
• I10: essential hypertension
• E11.9: type 2 diabetes without complications
• E78.5: hyperlipidemia, unspecified
• G47.33: obstructive sleep apnea (adult)
• E28.2: polycystic ovary syndrome (accepted at a growing number of plans)

The PA reviewer reads the patient chart for these codes attached to recent visits. Self-reported "I have high blood pressure" without an I10 in the chart, or a measured BP reading, will not satisfy. The codes need to be in the prescriber's submitted notes, not just on the PA form itself.

PBM-specific rules that change the answer

Three pharmacy benefit managers process roughly 80 percent of US commercial prescriptions: CVS Caremark, OptumRx and Express Scripts. Each runs the underlying plan's criteria through its own utilization-management overlay.

CVS Caremark

Tends to require the strictest lifestyle documentation. The published 2026 utilization criteria call for "6 consecutive months of clinically supervised diet, exercise and behavioral modification, documented in the medical record." Self-reported attempts do not count. A 30-day Noom subscription does not count. WeightWatchers attendance with receipts can count.

Caremark also runs aggressive step therapy on Zepbound: many plans require a 12 to 16 week failed semaglutide (Wegovy) trial before approving tirzepatide, unless the patient has a documented contraindication.

OptumRx

The most consistent of the three on initial criteria. The published criteria mirror the AACE guideline almost exactly. Lifestyle documentation can be 3 months instead of 6 if the prescriber attests to ongoing behavioral support within the practice. Less aggressive on Zepbound step therapy than Caremark, though plan-level overrides exist.

OptumRx also runs a separate weight-loss-medication formulary tier for some plans, which can shift the copay from $25 (preferred) to $150-plus (non-preferred) without changing the approval itself. Check the formulary, not just the PA outcome.

Express Scripts

The most variable. Express Scripts runs many self-insured employer plans with custom criteria, so the same patient can get approved on one employer plan and denied on another, both administered by Express Scripts. Read the specific plan's prior authorization document, not the generic Express Scripts policy.

Express Scripts published a 2025 update tightening obesity-medication step therapy: many plans now require Saxenda (liraglutide) or Contrave failure before Wegovy approval. This is unusual and is the single most common surprise denial we see in member reports.

Denial reasons, ranked by frequency

From the 2024 Kaiser Family Foundation employer-coverage survey and pulled member reports across 2025-2026, the denial categories break down roughly:

• 35-40 percent: insufficient lifestyle documentation. The chart does not show 6 months of supervised diet and exercise. This is the easiest denial to fix; the prescriber re-submits with a longer-look-back of visit notes mentioning dietary counseling, exercise prescription or referral to a registered dietitian.
• 20-25 percent: step therapy not met. The plan requires a prior failure on a cheaper or older anti-obesity medication. Either run the step (4 to 16 weeks on phentermine, Contrave or Saxenda, document the failure, then re-apply) or appeal with a medical-necessity letter explaining why the step is contraindicated.
• 15-20 percent: comorbidity not documented. The patient claimed hypertension on the PA form, but the chart does not have a recent I10 with measured BP readings. Fix: a blood pressure visit and a comorbidity-documentation appendix to the resubmission.
• 10 percent: BMI below threshold. The patient's chart shows BMI of 27.4 but no qualifying comorbidity, or BMI of 26.5 entirely. Limited fix: get the BMI documented above 27 on a fresh weigh-in, or add a comorbidity, or accept that the plan will not cover the drug.
• 5-10 percent: formulary exclusion. The plan does not cover Wegovy or Zepbound for weight loss at all. No PA path will fix this; the patient needs to switch to a covered drug or pay cash. See our coverage-change guide.
• 5 percent: clerical or coding error. Wrong NDC, wrong ICD-10, missing prescriber NPI. Trivial to fix on resubmission.

What step therapy actually means in practice

"Step therapy" means the plan wants you to fail on a cheaper drug first before it will pay for the more expensive one. For GLP-1 weight loss, the common step requirements are:

• Phentermine 37.5 mg daily for 4 to 12 weeks, with documented BMI plateau or weight regain
• Contrave (naltrexone-bupropion) for 12 to 16 weeks, with documented less-than-5 percent weight loss
• For Zepbound specifically, Wegovy or compounded semaglutide for 12 to 16 weeks with documented less-than-5 percent weight loss at maximum tolerated dose

Step therapy can be waived if the prescriber writes a medical-necessity letter explaining why the step drug is contraindicated. Common medical-necessity grounds: history of cardiovascular events (phentermine is a sympathomimetic, contraindicated in coronary disease), history of seizure or eating disorder (Contrave bupropion lowers seizure threshold and is contraindicated in eating disorders), or prior semaglutide failure already documented.

The medical-necessity letter is what most patients are missing when they get a step-therapy denial. Our step-therapy appeal template covers the standard arguments by plan.

What a successful PA letter contains

Prescribers who get high approval rates submit letters that include all of these. The omission of any one is the single most common denial driver:

1. Patient demographics, height, weight, BMI, calculated from a measurement in the last 90 days
2. The exact ICD-10 codes that establish eligibility (E66.x for obesity, plus comorbidity codes if at the 27-29.9 threshold)
3. A narrative of prior weight-loss attempts with dates: "6/2024 to 12/2024 monitored Mediterranean-pattern diet with weekly weigh-ins, weight at start 220 lb, weight at end 218 lb, 0.9 percent loss"
4. A narrative of prior anti-obesity medication trials with outcomes, if any
5. The requested medication, dose-titration plan and rationale ("semaglutide 2.4 mg weekly titrated per FDA label")
6. Citation of the registration trial evidence (STEP-1 for Wegovy, SURMOUNT-1 for Zepbound)
7. Attestation that the patient has been counseled on side effects, contraindications and the long-term-treatment expectation
8. If step therapy is being challenged: explicit medical-necessity rationale for why the step drug is contraindicated

If your prescriber does not include items 3, 4 and 7, the PA will likely come back asking for them. That round-trip adds 1 to 3 weeks. Our PA letter library has 60 plan-and-condition templates that contain all 8 items. They are free, no email gate.

Timeline expectations

A standard PA, submitted clean, with all 8 items above, takes:

• 3 to 7 business days at OptumRx
• 5 to 10 business days at CVS Caremark
• 5 to 15 business days at Express Scripts (varies by plan)

If you have not received a decision within those windows, your prescriber's office should call the PBM directly. Decisions sit in queues; a phone call routinely surfaces an answer that was already approved but not transmitted.

If denied, the appeal timeline adds 4 to 6 weeks for an internal appeal and another 4 to 6 weeks if you escalate to an external review through your state insurance commissioner. See our appeal-paths guide.

What programs handle this well

Telehealth programs that explicitly run prior authorization, and have member-reported approval rates above 70 percent on initial submission:

• PlushCare, in-network with most major carriers, runs PA as standard practice
• Form Health, obesity-medicine specialists, writes detailed comorbidity letters
• Knownwell, primary-care integrated, handles step-therapy documentation across multiple medications
• 9amHealth, comorbidity-focused intake, strong on diabetes-adjacent PAs

Compounded-only programs like Mochi and Henry Meds will not run PA on branded drugs. That is the cash-pay model; see our cash-pay rankings.

FAQ

Can I appeal a denial myself, or does my prescriber have to do it?

You can file the appeal yourself, but the clinical content needs to come from your prescriber. The appeal letter that wins overturns the denial reason directly: if the denial said "insufficient lifestyle documentation," the appeal needs to attach the lifestyle documentation that was missing, signed by the prescriber. Patient-written narrative without prescriber attestation rarely overturns a denial. See our appeal-letter library for plan-specific templates the prescriber can sign.

Does Medicare cover Wegovy or Zepbound for weight loss?

Medicare does not cover anti-obesity medications under Part D. This is a statutory exclusion under the Medicare Modernization Act of 2003. Medicare will cover Ozempic and Mounjaro for type 2 diabetes (under different criteria) and Wegovy for cardiovascular risk reduction in established CVD patients (a 2024 indication added after SELECT). For pure weight-loss indication on Medicare, expect to pay cash.

What counts as "medically supervised" diet and exercise?

The standard interpretation across PBMs is documentation in your medical record showing your PCP or another clinician reviewed your diet and exercise plan, monitored your weight at follow-up visits and made adjustments. A single mention of "discussed diet" at one visit will not qualify. Three to six follow-up visits across 6 months with weight measurements, dietary discussion and exercise prescription generally will. Structured programs like WeightWatchers Clinic or Optavia can count if the prescriber documents enrollment in the chart.

If my employer adds GLP-1 coverage mid-year, do I have to wait until open enrollment?

No. Mid-year formulary changes are immediate. If your employer adds Wegovy or Zepbound coverage in July, you can submit a PA in July. The catch is that some employer plans require a fresh 6-month lifestyle documentation period starting from the coverage date. Most do not, and recent documentation predating the coverage change generally counts.

Can I get approved if my BMI is exactly 30?

Yes. The threshold is BMI greater than or equal to 30, not strictly above 30. If your chart shows BMI 30.0 at a recent weigh-in, you meet the obesity threshold without needing a comorbidity. The risk is BMI drift: if you weigh in at 30.0 in March and 29.8 in June, the June reading can disqualify you on resubmission. Schedule the PA submission close to a confirmed BMI-30 weigh-in.